CD86 and glioblastoma: According to the TISIDB tool, we identified five immunoinhibitors (ADORA2A, KDR, PVRL2, TGFB1 and TGFBR1) and three immunostimulators (C10orf54, CD48 and CD86) that were significantly associated with PXDN expression in GBM (Figure 6).